This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series
Sustainability is integral to Biocon's business purpose
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
These re-agent and diagnostic test kits come with 99.7% accuracy
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Subscribe To Our Newsletter & Stay Updated
